Targeting PGE2 biosynthesis or signalling, using cyclooxygenase‐2 inhibitors or EP2/4 antagonists respectively, substantially increased responses to ICB therapy in mouse transplantable tumours by enhancing cDC1 infiltration and activity [115, 129]. Here, MPPE1 is linked to neoplasm.